Pharmacological Properties of Novel Cyclic Pentapeptides with µ-opioid Receptor Agonist Activity

ISSN: 1875-6638 (Online)
ISSN: 1573-4064 (Print)

Volume 13, 8 Issues, 2017

Download PDF Flyer

Medicinal Chemistry

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Honorary Life Fellow
Kings College
University of Cambridge

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.458
5 - Year: 1.423

Pharmacological Properties of Novel Cyclic Pentapeptides with µ-opioid Receptor Agonist Activity

Medicinal Chemistry, 10(2): 154-161.

Author(s): Renata Perlikowska, Justyna Piekielna, Jakub Fichna, Jean Claude do-Rego, Geza Toth, Tomasz Janecki and Anna Janecka.

Affiliation: Department of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.


In our previous paper we have reported the synthesis and biological activity of a cyclic analog, Tyr-c(D-Lys- Phe-Phe-Asp)-NH2, based on endomorphin-2 (EM-2) structure. This analog displayed high affinity for the µ -opioid receptor, was much more stable than EM-2 in rat brain homogenate and showed remarkable antinociceptive activity after intracerebroventricular (i.c.v.) injection. Even more importantly, the cyclic analog elicited weak analgesia also after peripheral administration, giving evidence that it was able to cross, at least to some extent, the blood-brain barrier (BBB). Here we describe further modifications of this analog aimed at enhancing brain delivery by increasing lipophilicity. Two new cyclic pentapeptides, Tyr-c(D-Lys-D-1-Nal-Phe-Asp)-NH2 and Tyr-c(D-Lys-D-2-Nal-Phe-Asp)-NH2 (where 1-Nal=1- naphthyl-3-alanine, 2-Nal=2-naphthyl-3-alanine) were synthesized and evaluated in biological assays. Both analogs showed high µ -opioid receptor affinity and agonist activity and were stable in the rat brain homogenates. Unfortunately, the increase of lipophilicity was achieved at the expense of water solubility. The analog with D-2-Nal residue showed strong analgesic effect when given i.c.v. but could not be tested after intravenous (i.v.) administration where higher concentrations of the compound are required. However, this analog showed inhibitory effect on gastrointestinal (GI) motility in vivo, providing an interesting approach to the development of peripherally restricted agents that could be useful for studying gastrointestinal disorders in animal models.


Binding studies, µ -, δ - opioid receptor, hot-plate test, solid phase peptide synthesis, blood-brain barrier, lipophilicity.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 10
Issue Number: 2
First Page: 154
Last Page: 161
Page Count: 8
DOI: 10.2174/157340641002140131161135
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science